Literature DB >> 17361112

Activation of the renin-angiotensin system within podocytes in diabetes.

T-H Yoo1, J-J Li, J-J Kim, D-S Jung, S-J Kwak, D-R Ryu, H Y Choi, J S Kim, H J Kim, S H Han, J E Lee, D S Han, S-W Kang.   

Abstract

The autocrine and paracrine activation of the renin-angiotensin system (RAS) within cells of the kidney plays a role in the overall pathophysiology of the renal disease due to diabetes. In this study, we focus on components of the RAS in the podocyte as these cells are important in the pathogenesis of glomerulosclerosis and proteinuria. Immortalized mouse podocytes were exposed to media containing normal glucose (NG) or high glucose (HG) for in vitro studies. In vivo studies utilized kidney tissue obtained from rats treated for 3 months with streptozotocin to induce diabetes. Angiotensinogen (AGT) and the angiotensin II (AII) type 1 receptor mRNA and protein were significantly increased in the podocytes cultured under the high glucose conditions. Both angiotensins I and II levels were significantly higher in cell lysates and the conditioned media of cells grown in high glucose. There were no differences in renin activity, angiotensin-converting enzyme level, or AII type 2 receptor level. Glomerular AGT and AII type 1 receptor assessed by means of immunohistochemistry were increased in diabetic rats compared with the control rats. Other measured components of the RAS within the glomeruli were not different. We suggest that increased AGT, an attendant increase in AII and increased AII type 1 receptor in podocytes experiencing diabetic conditions play an important role in the pathogenesis of diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17361112     DOI: 10.1038/sj.ki.5002195

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  35 in total

Review 1.  Intracardiac intracellular angiotensin system in diabetes.

Authors:  Rajesh Kumar; Qian Chen Yong; Candice M Thomas; Kenneth M Baker
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-14       Impact factor: 3.619

Review 2.  The intracrine renin-angiotensin system.

Authors:  Rajesh Kumar; Candice M Thomas; Qian Chen Yong; Wen Chen; Kenneth M Baker
Journal:  Clin Sci (Lond)       Date:  2012-09       Impact factor: 6.124

3.  Translationally controlled tumour protein is associated with podocyte hypertrophy in a mouse model of type 1 diabetes.

Authors:  D K Kim; B Y Nam; J J Li; J T Park; S H Lee; D H Kim; J Y Kim; H Y Kang; S H Han; T H Yoo; D S Han; S W Kang
Journal:  Diabetologia       Date:  2012-02-04       Impact factor: 10.122

Review 4.  The importance of the intrarenal renin-angiotensin system.

Authors:  Juan Carlos Q Velez
Journal:  Nat Clin Pract Nephrol       Date:  2008-12-09

Review 5.  Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?

Authors:  Janina Müller-Deile; Mario Schiffer
Journal:  Pediatr Nephrol       Date:  2015-05-05       Impact factor: 3.714

6.  ROCK/NF-κB axis-dependent augmentation of angiotensinogen by angiotensin II in primary-cultured preglomerular vascular smooth muscle cells.

Authors:  Kayoko Miyata; Ryousuke Satou; Weijian Shao; Minolfa C Prieto; Maki Urushihara; Hiroyuki Kobori; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2014-01-15

7.  Na+,K+-ATPase is modulated by angiotensin II in diabetic rat kidney--another reason for diabetic nephropathy?

Authors:  Andrea Fekete; Klara Rosta; Laszlo Wagner; Agnes Prokai; Peter Degrell; Eva Ruzicska; Edit Vegh; Miklos Toth; Katalin Ronai; Krisztina Rusai; Aniko Somogyi; Tivadar Tulassay; Attila J Szabo; Agota Ver
Journal:  J Physiol       Date:  2008-09-25       Impact factor: 5.182

Review 8.  Vitamin D and diabetic nephropathy.

Authors:  Yan Chun Li
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

9.  Role of upstream stimulatory factor 2 in diabetic nephropathy.

Authors:  Shuxia Wang
Journal:  Front Biol (Beijing)       Date:  2015-05-13

10.  Angiotensin II Type 1 Receptor Blockers Reduce Urinary Angiotensinogen Excretion and the Levels of Urinary Markers of Oxidative Stress and Inflammation in Patients with Type 2 Diabetic Nephropathy.

Authors:  Susumu Ogawa; Hiroyuki Kobori; Naro Ohashi; Maki Urushihara; Akira Nishiyama; Takefumi Mori; Tsuneo Ishizuka; Kazuhiro Nako; Sadayoshi Ito
Journal:  Biomark Insights       Date:  2009-06-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.